We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

21 hedge funds and large institutions have $7.02M invested in Evoke Pharma in 2017 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more capital invested

Capital invested by funds: $5.07M → $7.02M (+$1.95M)

0.79% more ownership

Funds ownership: 12.87% → 13.66% (+0.79%)

0% more funds holding

Funds holding: 21 → 21 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
21
Holders Change
–
Holders Change %
0%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$190K
2
Millennium Management
Millennium Management
New York
+$147K
3
KCM
Knoll Capital Management
Florida
+$134K
4
VF
Virtu Financial
New York
+$106K
5
TSS
Two Sigma Securities
New York
+$29.7K

Top Sellers

Rank Fund Capital Flow
1
PM
Precept Management
Texas
-$243K
2
ARTA
A.R.T. Advisors
New York
-$39K

EVOK Hedge Fund Activity: Q3 2017 in Review

21 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2017, worth a combined $7.02M — up 38% from $5.07M a quarter earlier.

Fund positioning in EVOK was balanced in Q3 2017: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 0 trimmed.

The largest buyer was Sphera Funds Management, adding an estimated $190K. The largest seller was Precept Management, exiting entirely with an estimated $243K sold.

  • 21 institutional investors held Evoke Pharma (EVOK) as of Q3 2017, unchanged from Q2 2017.
  • Funds reported $7.02M of Evoke Pharma stock for Q3 2017, up 38% quarter-over-quarter.
  • 4 funds opened new Evoke Pharma positions in Q3 2017 and 4 closed out, a net change of 0 holders.
  • The largest Evoke Pharma buyer in Q3 2017 was Sphera Funds Management, an estimated $190K added.
  • The largest Evoke Pharma seller in Q3 2017 was Precept Management, an estimated $243K sold.

Based on aggregated 13F filings for Q3 2017.